Objectives: Results of the ALEX trial demonstrated that alectinib decreased the risk of Central Nervous System (CNS) progression and prolonged progression-free survival of NSCLC ALK+ patients, compared with crizotinib. The objective of this study is to compare the economic burden of CNS progression with alectinib versus crizotinib, on the Brazilian private healthcare system. Conclusions: Alectinib can potentially decrease the economic burden of CNS metastasis of NSCLC ALK+ patients in the Brazilian private healthcare system, compared with the current standard of care. READ ARTICLE
Value in Health DOI:10.1016/j.jval.2019.04.253
Authors: D.Kashiura, M.Santos, L.Carmo, R.Leme-Souza
